{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:35:52Z","timestamp":1793810152982,"version":"4.6.1"},"reference-count":98,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bladder Cancer"],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Advanced urothelial carcinoma (UC) is an aggressive disease whose mutagenic processes are yet to be elucidated. Targeted therapies are urgently needed, but the road from bench to bedside is slowly progressing. In this review, we discuss urothelial carcinoma etiology, along with the most recent advances in UC candidate targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>METHODOLOGY:<\/jats:title>\n                    <jats:p>A comprehensive database search was performed. We aimed to review the most recent updates on UC genomics and targeted therapies. Pre-clinical as well as clinical studies were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Our review highlights the advances in understanding the molecular basis of urothelial tumorigenesis, including smoking, chemical parasitic carcinogens, inheritance, and APOBEC3 editing enzymes. We discussed how these factors contributed to the current mutational landscape of UC. Therapeutic options for UC are still very limited. However, several promising therapeutic approaches are in development to leverage our knowledge of molecular targets, such as targeting fibroblast growth factor receptors (FGFR), DNA damage repair pathways, and HER2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Blindly testing targeted therapies based on other cancer data is not sufficient. UC-specific biomarkers are needed to precisely use the appropriate drug for the appropriate population. More efforts to understand UC biology and evolution are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/blc-230025","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T11:23:36Z","timestamp":1700220216000},"page":"313-322","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets"],"prefix":"10.1177","volume":"9","author":[{"given":"Rana M.","family":"Abdeltwab","sequence":"first","affiliation":[{"name":"Cairo University","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaria","family":"Yacoub","sequence":"additional","affiliation":[{"name":"Cairo University","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Rashad","sequence":"additional","affiliation":[{"name":"Cairo University","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrillus S.","family":"Shohdy","sequence":"additional","affiliation":[{"name":"The University of Glasgow","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"SEER. Cancer Stat Facts: Bladder Cancer. 2019."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176072"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.09.017"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","unstructured":"Lukinich-gruiaAT PavloviNM MilovanoviD TatuA ChemosphereAristolochic acid I as an emerging biogenic contaminant involved inchronic kidney diseases: A comprehensive review on exposurepathways environmental health issues and future challenges. 2022;297(February).","DOI":"10.1016\/j.chemosphere.2022.134111"},{"key":"e_1_3_5_10_2","doi-asserted-by":"crossref","unstructured":"XiaoJ ZhuX HaoGY ZhuYC HouHJ ZhangJ et al. Transplantation and Aristolochic Acid Exposure: The Potential Roleof Aristolochic Acid in HRas and TP53 Gene Mutations. 2011;3754:3751\u20134.","DOI":"10.1016\/j.transproceed.2011.09.069"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","unstructured":"Anne Lemy Karl WissingM Sandrine RoriveAZ Late Onset of Bladder Urothelial Carcinoma After Kidney Transplantation for End-Stage Aristolochic Acid Nephropathy: A Case Series With 15-Year Follow-u. 2008;51(3):471\u20137.","DOI":"10.1053\/j.ajkd.2007.11.015"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006086"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0161-3"},{"issue":"6","key":"e_1_3_5_14_2","first-page":"259","article-title":"Vaccine against arteriosclerosis: an update","volume":"9","author":"Soiza RL","year":"2018","unstructured":"SoizaRL, DonaldsonAIC, MyintPK Vaccine against arteriosclerosis: an update. Ther Adv Vaccines. 2018;9(6):259\u201361.","journal-title":"Ther Adv Vaccines"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","unstructured":"Lukinich-gruiaAT PavloviNM MilovanoviD TatuA ChemosphereAristolochic acid I as an emerging biogenic contaminant involved inchronic kidney diseases: A comprehensive review on exposurepathways environmental health issues and future challenges. 2022;297(February).","DOI":"10.1016\/j.chemosphere.2022.134111"},{"key":"e_1_3_5_16_2","doi-asserted-by":"crossref","unstructured":"WuL TruongS MoriyaM SladeN BrdarB MedverecZ et al. TP 53Mutational signature for aristolochic acid: an environmentalcarcinogen. 2011;1536:1532\u20136.","DOI":"10.1002\/ijc.26077"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","unstructured":"NedelkoT ArltVM PhillipsDH HollsteinM SHORT REPORT TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. 2009;990(September 2008):987\u201390.","DOI":"10.1002\/ijc.24006"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","unstructured":"XiaoJ ZhuX HaoGY ZhuYC HouHJ ZhangJ et al. Transplantation and Aristolochic Acid Exposure: The Potential Roleof Aristolochic Acid in HRas and TP53 Gene Mutations 2011;3754:3751\u20134.","DOI":"10.1016\/j.transproceed.2011.09.069"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","unstructured":"WangY MengF ArltVM MeiN ChenT ParsonsBL Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H- Ras and K- Ras mutant fraction. 2011;26(5):619\u201328.","DOI":"10.1093\/mutage\/ger023"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03059-3"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050728"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2257-z"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/03008880802325309"},{"key":"e_1_3_5_24_2","first-page":"1","article-title":"The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults","volume":"4","author":"Lewis DA","year":"2013","unstructured":"LewisDA, BrownR, WilliamsJ, WhiteP, JacobsonSK, MarchesiJR et al. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Front Cell Infect Microbiol. 2013;4(AUG):1\u201314.","journal-title":"Front Cell Infect Microbiol"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.361"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0013-8"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-27"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2007.04.010"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-020-00055-z"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","unstructured":"AshourDS Parasite \u2013bacteria interrelationshi. 2020;3145\u201364.","DOI":"10.1007\/s00436-020-06804-2"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.09.017"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000368"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0579-3"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0579-3"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5264"},{"key":"e_1_3_5_37_2","unstructured":"RobertsSA LawrenceMS KlimczakLJ GrimmSA StojanovP KiezunA et al. NIH Public Access. 2013;45(9):970\u20136."},{"key":"e_1_3_5_38_2","unstructured":"Nik-zainalS AlexandrovLB WedgeDC Loo VanP GreenmanCD RaineK et al. Mutational Processes Molding the Genomes of 21 Breast Cancers. 2012;979\u201393."},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.5261"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0026-y"},{"key":"e_1_3_5_41_2","doi-asserted-by":"crossref","unstructured":"MishraN Human APOBEC3B interacts with the heterogenous nuclear ribonucleoprotein A3 in cancer cells. 2017;(November 2017):6695\u2013703.","DOI":"10.1002\/jcb.26855"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006086"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13010124"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1530\/JME-19-0011"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02235-8"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207714"},{"issue":"15","key":"e_1_3_5_47_2","first-page":"1","article-title":"medical sciences Epidemiology of Bladder Cancer","volume":"8","author":"Saginala K","year":"2020","unstructured":"SaginalaK, BarsoukA, AluruJS, RawlaP, PadalaSA, BarsoukA medical sciences Epidemiology of Bladder Cancer. Medical Sciences. 2020;8(15):1\u201312.","journal-title":"Medical Sciences"},{"key":"e_1_3_5_48_2","first-page":"1","article-title":"Basis of Inheritance in Humans","volume":"30","author":"Vieira AR","year":"2021","unstructured":"VieiraAR Basis of Inheritance in Humans. Monogr Oral Sci. 2021;30, 1\u201319.","journal-title":"Monogr Oral Sci"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0743"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2017.03.003"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.17703"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01395"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0720-x"},{"key":"e_1_3_5_54_2","doi-asserted-by":"crossref","unstructured":"Sj\u00f6dahlG ErikssonP PatschanO Marzouka al dainN JakobssonL BernardoC et al. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. 2020;2647(May 2019):2636\u201347.","DOI":"10.1002\/ijc.32737"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.33"},{"key":"e_1_3_5_57_2","unstructured":"ThiemS HeroldT KrafftU BremmerF TolkachY SzAM Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. 2017;1\u20135."},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.132"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.04.037"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095724"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8640"},{"key":"e_1_3_5_62_2","unstructured":"COSMIC v89. Entry: Bladder Carcinoma Squamous cell carcinoma."},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12198"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2655"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0192-5"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01157-0"},{"issue":"1","key":"e_1_3_5_67_2","first-page":"1","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen CB","year":"2021","unstructured":"WestphalenCB, KrebsMG, Le TourneauC, SokolES, MaundSL, WilsonTR et al. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5(1):1\u20139.","journal-title":"NPJ Precis Oncol"},{"issue":"23","key":"e_1_3_5_68_2","first-page":"2964","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"72","author":"Emiliano Cocco","year":"2018","unstructured":"Emiliano Cocco1, Maurizio Scaltriti1, 2, 2, Alexander Drilon3, 4 NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;72(23):2964\u201379.","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00183"},{"issue":"1","key":"e_1_3_5_70_2","first-page":"1","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen CB","year":"2021","unstructured":"WestphalenCB, KrebsMG, Le TourneauC, SokolES, MaundSL, WilsonTR et al. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5(1):1\u20139.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"e_1_3_5_71_2","first-page":"1","article-title":"Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer","volume":"21","author":"Zhang Z","year":"2021","unstructured":"ZhangZ, YuY, ZhangP, MaG, ZhangM, LiangY et al. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer. BMC Cancer. 2021;21(1):1\u201313.","journal-title":"BMC Cancer"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01536-1"},{"key":"e_1_3_5_73_2","unstructured":"DrilonA LaetschTW KummarS DuboisSG LassenUN DemetriGD et al. HHS Public Access. 2018;378(8):731\u20139."},{"key":"e_1_3_5_74_2","unstructured":"No Title."},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103074"},{"key":"e_1_3_5_76_2","unstructured":"YoK CattoJ Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma. 2016;1\u20136."},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0023-9"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.027"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.06.009"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.30699\/ijp.2020.130859.2447"},{"key":"e_1_3_5_81_2","doi-asserted-by":"crossref","unstructured":"RedaM OchiE OukabliM BouaitiE ChahdiH BoudhasA et al. Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. 2017;13\u20137.","DOI":"10.1186\/s12907-017-0046-z"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12345"},{"key":"e_1_3_5_83_2","doi-asserted-by":"crossref","unstructured":"GanK GaoY LiuK XuB QinW The Clinical Signi fi cance andPrognostic Value of HER2 Expression in Bladder Cancer: AMeta-Analysis and a Bioinformatic Analysis. 2021;11(September).","DOI":"10.3389\/fonc.2021.653491"},{"key":"e_1_3_5_84_2","unstructured":"MichaelsonMD HuC PhamHT DahlDM SouhamiL ChangB et al. HHS Public Access. 2018;97(5):995\u20131001."},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519895847"},{"key":"e_1_3_5_86_2","unstructured":"JrPNL ChattaGS NanusDM GlodeLM TrumpDL ChenH et al. Trastuzumab Paclitaxel Carboplatin and Gemcitabine in AdvancedHuman Epidermal Growth Factor Receptor-2 \/ neu \u2013PositiveUrothelial Carcinoma: Results of a Multicenter Phase II NationalCancer Institute Trial. 2022;25(16)."},{"key":"e_1_3_5_87_2","unstructured":"MichaelsonMD HuC PhamHT DahlDM SouhamiL ChangB et al. HHS Public Access. 2018;97(5):995\u20131001."},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1159\/000443280"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.009"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.07.015"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2014.987662"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.01.003"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08085-z"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz249.001"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1382-1"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19971-8"},{"issue":"6","key":"e_1_3_5_97_2","first-page":"1","article-title":"Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC","volume":"12","author":"Yang H","year":"2020","unstructured":"YangH, LiuZ, WangY, LiJ, LiR, WangQ et al. Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC. Ther Adv Med Oncol. 2020;12(6):1\u20138.","journal-title":"Ther Adv Med Oncol"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.440"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4505"}],"container-title":["Bladder Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-230025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/BLC-230025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-230025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:21:25Z","timestamp":1777382485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/BLC-230025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11,17]]}},"alternative-id":["10.3233\/BLC-230025"],"URL":"https:\/\/doi.org\/10.3233\/blc-230025","relation":{},"ISSN":["2352-3727","2352-3735"],"issn-type":[{"value":"2352-3727","type":"print"},{"value":"2352-3735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}